Survival outcomes and risk group validation from SWOG S0925: a randomized phase II study of cixutumumab in new metastatic hormone-sensitive prostate cancer

Prostate Cancer and Prostatic Diseases, Published online: 13 February 2020; doi:10.1038/s41391-020-0210-xSurvival outcomes and risk group validation from SWOG S0925: a randomized phase II study of cixutumumab in new metastatic hormone-sensitive prostate cancer

Source: Prostate Cancer and Prostatic Diseases - February 12, 2020 Category: Urology & Nephrology Authors: Risa L. Wong Mai T. Duong Catherine M. Tangen Neeraj Agarwal Heather H. Cheng Nicholas J. Vogelzang Maha Hussain Ian M. Thompson Jr. David I. Quinn Evan Y. Yu Source Type: research